SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: SHR-A1811|DRUG: Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
Sponsor: Jiangsu HengRui Medicine Co., Ltd.